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ABSTRACT 
 
 Pulmonary hypertension (PH) is a disease which manifests itself in the lungs of 
both adults and children.  Vascular proliferation and remodeling are the hallmarks of PH 
and are found mainly in the pulmonary arterial smooth muscle cells (PASMC).  The 
cause of PASMC proliferation and vascular remodeling in PH is poorly understood. 
Hypoxia, or low oxygen content, underlies many forms of PH.  Hypoxia results in 
alterations in the redox balance of the PASMC.  Therefore, the aim of this study was to 
examine the role of the thioredoxin system, an antioxidant system in the cell, in hypoxia-
induced proliferation in PASMC.  Protein was isolated from human PASMC which were 
exposed to either hypoxia (1% O2, 5% CO2, balance N2) or normoxia (21% O2, 5% CO2 
and balance N2) to determine the protein levels of thioredoxin 1 and 2 (Trx1 and Trx2), 
thioredoxin reductase (TrxR), and thioredoxin interacting protein (Txnip), by Western 
blotting.  Proliferation studies were also done by seeding 6 well plates with 10,000 
PASMC per well, incubating in either normoxia or hypoxia for 5 days and counting viable 
cells using trypan blue exclusion.  We found that in hypoxia the Trx1 protein levels were 
significantly greater after 48 and 72 hours of exposure than in PASMC grown in 
normoxia.  We also found that PASMC proliferate more in hypoxia than in normoxia. To 
determine if Trx1 had a role in hypoxia-induced PASMC proliferation we knocked down 
Trx1 protein in the PASMC using specific siRNA, and treatment with the Trx1 siRNA 
completely prevented hypoxia-induced proliferation in PASMC.  These findings 
demonstrate that Trx1 protein is necessary for the hypoxia-induced proliferation of 
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PASMC.  We speculate that Trx1 may represent a novel therapeutic target for the 
vascular remodeling that underlies PH. 
 
 
Key Words: Pulmonary hypertension, proliferation, vascular remodeling, thioredoxin 1 
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CHAPTER 1 
BACKGROUND 
 
Pulmonary hypertension (PH) is seen in both children and adults and is 
associated with a clinical course of progressive deterioration interspersed with episodes 
of acute decompensation (Gaile, 2009). There is no cure for pulmonary hypertension 
(Ferns, 2009).  The 5 year survival rate in patients with idiopathic pulmonary arterial 
hypertension treated with the vasodilator epoprostenol has been reported to be 
approximately 50% (McLaughlin, 2002). In children the outcomes may be even worse, 
for patients with chronic neonatal lung disease and PH the 2 year survival is only 25%, 
while the 2 year survival for patients with chronic neonatal lung disease and no evidence 
of PH is about 80% (Khemani, 2007).  
It is now recognized that vascular proliferation and remodeling are the hallmark 
of PH (Morrell, 2009). The process of pulmonary vascular remodeling involves all layers 
of the vessel wall, and smooth muscle cells have a central role in vascular remodeling 
(Morrell, 2009). The proliferation and remodeling of the cell layers in the walls of the 
pulmonary arteries cause the lumens of the vessels to decrease in size.  This causes an 
increase in blood pressure within these vessels and therefore the right side of the heart 
also increases in size because it must work harder to pump blood throughout the 
pulmonary circuit.  Currently available therapies for PH treat only the symptoms of PH. 
The available therapies include vasodilator therapies which dilate the blood vessels but 
do not reverse pulmonary vascular remodeling (Ferns, 2009). There have been  
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improvements in patient outcomes, although there are no curative therapies (Ghofrani, 
2009).  Often the success of therapy is measured in improvements in the distance 
walked in 6 minutes (the 6 minute walk test). Thus, new therapies and/or novel 
therapeutic approaches are desperately needed for this devastating disease.  
Oxidative stress also has an important role in the development and the advance 
of PH.  Recent data implicated oxidative stress as a mediator of PH and of the 
associated pathological changes to the pulmonary vasculature (DeMarco, 2010).  
Oxidative stress occurs when external insults cause excess reactive oxygen species 
(ROS) formation which overwhelms the antioxidant systems and creates an imbalance in 
the redox state of the cell, favoring oxidation.  Excess ROS synthesis results in cell and 
tissue damage.  Oxidative stress can contribute significantly to the pathogenesis of PH 
(DeMarco, 2010).  Because ROS may promote vascular remodeling and smooth muscle 
cell proliferation, they are likely to play a significant role in many forms of PH (DeMarco, 
2010). There are various types of ROS which are correlated with cardiovascular 
diseases, including superoxide (O2•-) and hydrogen peroxide (H2O2).  ROS are harmful to 
subcellular organelles, like proteins, lipids, carbohydrates, and DNA, and thus a system 
to limit their action is necessary for cell survival, the antioxidant system.  An example of 
an antioxidant system is the thioredoxin system, which acts as a thiol-reducing system 
(Park, 2010). 
Thioredoxin (Trx), a ubiquitously expressed 12 kDa protein that along with 
thioredoxin reductase (TrxR) constitutes the Trx system, which is important in 
maintaining the oxidative balance inside of the cell. There are 2 isoforms of Trx, Trx1 is 
the predominant form of the thioredoxin protein, and Trx2 which is an 18 kDa protein that 
contains a 60 residue N-terminal sequence for targeting to the mitochondria (Collet, 
2010).  TrxR reduces oxidized Trx so that Trx can act as an electron donor to  
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peroxidases and ribonucleotide reductases in the cell, which then eliminate ROS in the 
cell (Park, 2010).  However, Trx tends to exert most of its ROS-scavenging properties 
through Trx peroxidase, which is reduced by Trx1 and can scavenge ROS, like H2O2 by 
breaking it down into water and alcohol (Yamawaki, 2003). Thus, thioredoxins are 
essential for cell life in mammals. Thioredoxin interacting protein (Txnip) is another 
component of the Trx system, and acts as a negative regulator of Trx function, inhibiting 
its activity by interacting with the catalytic site of Trx (World, 2006).  There is also 
evidence that Txnip has a role in cardiovascular disorders, like PH, by functioning as a 
sensor for oxidative stress (World, 2006). 
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(Trx-dependent peroxidases) to scavenge
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PH is defined by a mean pulmonary artery pressure (PAP) in excess of 25 mmHg 
at rest (DeMarco, 2010).  Hypoxia induces an immediate increase in PAP, and initiates 
and sustains an inflammatory response over time.  Because of these changes, 
especially the increase in the number of inflammatory cells, there is also an increase in 
ROS during hypoxia (DeMarco, 2010).  Thus, hypoxia can be used as an ideal model of 
PH.   
Trx1 expression in some cells types can be augmented following hypoxic 
exposure.  For example, Trx1 expression is shown to significantly increase in response 
to hypoxia exposure in rat hippocampal neurons (Stroev, 2009).  Trx1 expression has 
also been shown to be elevated in response to hypoxia in human lung cancer tissues 
(Kim, 2003). Trx1 is also known to have a direct growth stimulating activity (Berggren, 
1996) and proliferation increases as a result of Trx1 secretion.  The role of Trx1 in 
hypoxia-induced proliferation and remodeling in PASMC has not been studied.  
Therefore, we hypothesized that as a result of hypoxia; Trx1 protein expression in 
PASMC will increase, and as a result, so will the proliferation of these cells. 
RNA interference (RNAi) is a process to regulate gene expression within the cell.  
In order to suppress gene expression, a RNAi gene-silencing technique uses small-
interfering RNA (siRNA).  A specific siRNA will target a specific mRNA sequence within 
the cell, and is directed to this target RNA by an RNAi induced silencing complex 
(RISC).  The antisense strand of the siRNA, along with RISC, directs the degradation of 
the complementary mRNA.  One of the most common ways in which siRNA is 
introduced to the cell is through transfection.  Transfection is conducted following a 
specific protocol, which includes using a scramble siRNA as a positive control.  The 
scramble siRNA is made up of the same nucleotides as the siRNA, however, they are 
arranged in a different order which does not affect expression of the target mRNA. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
Pulmonary arterial smooth muscle cell (PASMC) culture: Human PASMC (Lonza 
Group Ltd, Switzerland) are grown in 21% O2, 5% CO2, balance N2 at 37°C in smooth 
muscle growth media (SmGM, Lonza), which includes 5% fetal bovine serum, 0.5 ng/ml 
human recombinant epidermal growth factor, 2 ng/ml human recombinant fibroblast 
growth factor, 5 µg/ml insulin and 50 µg/ml of gentamicin.  The hPASMC are used in 
experiments between the fifth and eighth passages, throughout which no changes in cell 
morphology are noted. The cells are grown to ~80-90% confluence, washed, fresh 
media is placed on the cells, and they are incubated in 21% O2, 5% CO2, balance N2 
(normoxia) or 1% O2, 5% CO2, balance N2 (hypoxia) for 24, 48, 72, or 120 hours.  
Protein isolation.  Protein is isolated from hPASMC as previously described 
(Nelin, 2001). Briefly, hPASMC are washed with phosphate-buffered saline (PBS), and 
50-100 µl of lysis buffer (0.2M NaOH, 0.2% SDS) is added to each plate or each well of 
a six-well plate. 30 minutes before use, the following protease inhibitors are added to 
each ml of lysis buffer: 1µl aprotinin [10 mg/ml double distilled (dd) H2O], 1µl leupeptin 
(10 mg/ml ddH2O), and 1µl of phenylmethylsulfonyl fluoride (34.8 mg/ml methanol). The 
lysis buffer solution is added to each plate or each well of a six-well plate. The hPASMC 
are scraped, pipetted into sterile centrifuge tubes, and placed on ice for 30 minutes. The 
cell lysates are centrifuged at 12,000 x g for 10 minutes. The supernatant is stored in 1.5  
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ml tubes at -80°C. Total protein concentration is determined by the Bradford method 
(Bio-Rad, Hercules, CA). 
Western Blot.  The lysed hPASMC are assayed for Trx1, Trx2, TrxR and Txnip 
protein levels by western blot analysis as previously described (Chen, 2009). Aliquots of 
cell lysate are diluted 1:1 with SDS sample buffer, heated to 80°C for 15 minutes, and 
then centrifuged at 10,000 x g at room temperature for 2 minutes. Aliquots of the 
supernatant are used for SDS-polyacrylamide gel electrophoresis. The proteins are 
transferred to polyvinylidene difluoride membranes and blocked for two hours in PBS 
with 0.1% Tween (PBS-T) containing 10% nonfat dried milk. The membranes are then 
incubated with primary antibody, Trx1, Trx2, TrxR or Txnip, overnight and then washed 
three times with PBS-T. The membranes are incubated with horseradish peroxidase-
conjugated goat anti-rabbit IgG secondary antibody (1:10,000, Bio-Rad) for 1h, then 
washed 3 times with PBS-T. The protein bands are visualized using enhanced 
chemiluminescence (ECL plus reagent; Amersham Pharmacia Biotech, Piscataway, NJ) 
and quantified using densitometry (Sigma Gel, Jandel Scientific, San Rafael, CA). To 
control for protein loading, the blots are stripped using a stripping buffer containing 62.5 
mM Tris HCl (pH 6.8), 2% SDS, and 100 mM 2-β-mercaptoethanol, and the blots are 
reprobed for β-actin (1:10,000; Abcam, Cambridge, MA).  
Proliferation Assay.  To determine cell proliferation, hPASMC (Lonza) are seeded 
in 6-well plates (~10,000 cells per well) in SmGM and incubated in normoxia or hypoxia 
for 120 hours. Adherent cells are trypsinized, and viable cells counted using a 
hemacytometer and trypan blue exclusion. 
Transfection. To determine the effects of Trx1 knock-down on hPASMC 
proliferation, transient transfection of the siRNA for the Trx1 gene was performed with  
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DharmaFECT 1 transfection reagent (Thermo Fisher Scientific, Lafayette, CO) according 
to manufacturer’s protocol. Briefly, in two 1.5 ml centrifuge tubes, 17.5 µL of 2 µM Trx1 
siRNA or scramble siRNA, was mixed with 17.5 µL of serum-free smooth muscle basal 
medium (Lonza), vortexed and incubated at room temperature for 5 minutes. In two 
separate 1.5 ml centrifuge tubes, 1.4 µL of the DharmaFECT transfection reagent was 
mixed with 33.6 µL of serum-free smooth muscle basal medium (Lonza), vortexed and 
incubated at room temperature for 5 minutes. One of the transfection reagent tubes was 
then added to the each tube of the siRNA mixture, mixed, and incubated at room 
temperature for 20 minutes. SmGM (280 µL) was then added to each tube for a total 
volume of 350 µl. For the vehicle-treated hPASMC, ddH20 was used in place of siRNA.   
Statistical Analysis.  The data are shown as mean +/- standard error.  The protein 
levels for each protein of interest were compared for effects of time and oxygen tension 
using a two-way analysis of variance (ANOVA).  The protein levels for normoxic and 
hypoxic values were compared at individual time points using a t-test.  The proliferation 
studies were compared using a one-way ANOVA with a student Newman Keuls post-hoc 
test to identify group differences.  Differences were considered significant when p<0.05. 
Experimental Protocols: In the first set of studies, the expression levels of Trx1, 
Trx2, TrxR and Txnip proteins in PASMC cultured in either normoxia or hypoxia were 
determined.  The PASMC were grown for 24, 48, 72, and 120 hours as described above, 
and incubated in either normoxia or hypoxia.  At each time point, protein was harvested 
and used in Western blotting analysis for Trx1, Trx2, TrxR, and Txnip protein levels.  
Experiments were repeated 4-6 times for statistical analysis.   
In a second set of experiments, PASMC were used in proliferation assays as 
described above.  The PASMC were transfected with either a Trx1 siRNA construct or a 
scramble siRNA construct as described above, and placed in either normoxia or  
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hypoxia, such that there were 6 groups, normoxic vehicle treated, normoxic Trx1 siRNA 
treated, normoxic scramble siRNA treated, hypoxic vehicle treated, hypoxic Trx1 siRNA 
treated and hypoxic scramble siRNA treated.  After 120 hours the PASMC were 
harvested and counted as described above.  Some of the PASMC from the wells are 
harvested for protein so that Western blot analysis can be done to confirm knock-down 
of Trx1.  Experiments were repeated 4-6 times for statistical analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
  
 
 
 
CHAPTER 3 
RESULTS 
 
 The effect of hypoxia on the expression of the thioredoxin proteins. The hPASMC 
were exposed to either hypoxia or normoxia for various times (24 hours, 48 hours, 72 
hours, and 120 hours).  At each time point the protein was harvested and stored in the -
80˚C freezer.  The protein concentration of the cell lysates was then determined and 
samples for Western blotting made. Western blot analysis was conducted with primary 
antibodies against Trx1, Trx2, Txnip, and TrxR.  We found that the expression of Trx1 
protein was significantly (p<0.001) higher after 72 hours of hypoxia than in cells exposed 
to normoxia for 72 hours; the expression of Trx1 in hypoxia appeared higher than in 
normoxia after 48 hours as well, however this difference was not significant (p=0.06) 
(Figure 2).  This trend may become significant if more experiments were done.  By a 
two-way ANOVA, we determined that for Trx1 there was interaction between the time of 
exposure and the oxygen tension of the exposure (p<0.001) (Figure 2).  We also found 
that Trx2, TrxR and Txnip are all expressed in the hPASMC (Figure 3).  However, 
hypoxia had little effect on the protein levels of Trx2, TrxR or Txnip and there was no 
interaction between the time of exposure and the oxygen tension of the exposure (Figure 
3).   
 Expression of Trx1 protein is prevented by the siRNA transfection in normoxia 
and hypoxia.  We found that the transfection of the hPASMC with the siRNA against 
Trx1 was successful in knocking down Trx1 protein expression (Figure 4).  There were  
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no discernable bands on the Trx1 Western blot in lanes containing the Trx1 siRNA 
treated hPASMC (lanes 1-4) and easily discernable bands on the β-actin Western blot in 
the same lanes, thus demonstrating the knockdown of Trx1 protein expression.  Lanes 
5-8 showed the expression of Trx1 in hPASMC treated with scramble siRNA, which is a 
construct that has the same nucleotide bases but is arranged in a different order.  This 
scramble siRNA functions as a control.  Lanes 9-12 represent the hPASMC vehicle 
treated samples, which are treated with ddH2O instead of an siRNA construct.  This 
figure not only shows Trx1 knockdown, but also reaffirms the fact that Trx1 protein 
expression is higher in hypoxia than in normoxia.  By observing the difference in band 
intensity of the control lanes, it can be seen that lanes 9 and 10 (hypoxia-exposed) are 
much darker than lanes 11 and 12 (normoxia-exposed).  This means that Trx1 was 
expressed at a higher level in the samples exposed to hypoxia than those exposed to 
normoxia. 
 Hypoxia-induced proliferation depends on Trx1 protein. Our proliferation studies 
revealed that Trx1 is an important factor in the hypoxia-induced proliferation of hPASMC 
(Figure 5).  After the knockdown of Trx1 with the siRNA construct, we determined the 
proliferation of these transfected hPASMC in both normoxia and hypoxia by counting the 
viable hPASMC in each well of a 6-well plate.  We found that the proliferation of 
hPASMC treated with the siRNA targeting Trx1 was the same in hypoxia as it was in 
normoxia.  Whereas in our experiments with scramble hPASMC, we found the 
proliferation to be much higher in hypoxia than in normoxia.  In the cells treated with the 
scramble siRNA construct the proliferation of hPASMC was significantly higher in 
hypoxia (p<0.001) than in normoxia.  Also in both exposure groups, hypoxia and 
normoxia, the proliferation of the cells treated with the siRNA targeting Trx1 was 
significantly less than that of the cells treated with the scramble siRNA (p<0.01). 
10 
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Figure 2. Thioredoxin 1 protein expression in hypox ia is significantly higher
than in normoxia at 48 hours and 72 hours. hPASMC were exposed to
hypoxia and normoxia over specified periods of time. They were then
assayed with a primary antibody against Trx1 to determine the level of
express ion of the Trx1 protein in the hPASMC. * Trx1 expression in hypoxia
different than normoxia at same time point (p<0.05).
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Figure 3. Trx2, TrxR1, and Txnip expression levels are largely unaffected by
exposure to hypoxia. hPASMC exposed to hypoxia and normoxia over
specif ied periods of time were assayed with primary antibodies against
Trx2, TrxR, and Txnip. The expression levels of these proteins were not
significantly different in the two condit ions. * expression in hypoxia different
from normoxia at the same time point (p<0.05).
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Figure 4. siRNA transfection of hPASMC with siRNA targeting Trx1 effectively knocks
down Trx1 protein expression. hPASMC were transfected with a siRNA targeting Trx1
and then exposed to hypoxia or normoxia for 120 hours . The controls were samples
of hPASMC treated with a scramble siRNA and hPASMC treated with no siRNA. Trx1
expression was effect ively s ilenced by the siRNA transfec tion, shown by the
disappearance of bands 1-4 in the Trx1 (12 kDa) Western Blot assay but not in the ß-
actin (42 kDa) assay. This figure again demonstrates that Trx1 expression is higher in
hypoxia (1%) than in normoxia (21%). On the Trx1-assayed blot, the band intensity is
much higher in the hypoxia-exposed control samples (lanes 9 and 10) than in the
normoxia-exposed control samples (lanes 11 and 12). (Control samples are simply
hPASMC treated with transfection reagent and ddH2O)
1% 1% 1%21% 21%21%
Trx1 siRNA Scramble 
siRNA
Control 
1% 1% 1%21% 21%21%
Trx1 siRNA Scramble 
siRNA
Control 
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Figure 5. Hypoxia-induced proliferat ion of hPASMC depends on Trx1. hPASMC
were transfected with either a scramble siRNA or an siRNA targeting Trx1. After
24 hours the cells were washed and allowed to recover for 24 hours. The cells
were then plated into the wells of a 6 well plate at a density of 10,000 cells per
well and 5 days later cell numbers were determined using trypan blue exclusion.
* Trx1 siRNA different from scramble siRNA same condition, p<0.01. # hypoxia
different from normoxia same treatment, p<0.001. hPASMC proliferation is
significantly higher in hypoxia compared to normoxia, however after transfection
with Trx1 siRNA (knockdown of gene expression), the proliferat ion of hPASMC
is the same in both normoxia and hypoxia.
  
 
 
CHAPTER 4 
DISCUSSION 
 
 The main findings from this study were that in hPASMC: 1) hypoxia increased the 
expression of Trx1 protein, 2) Trx1 protein levels could be knocked-down using an 
siRNA, 3) hypoxia increased proliferation of hPASMC and 4) knock-down of Trx1 protein 
prevented hypoxia-induced proliferation in hPASMC.  Our results confirm our hypothesis 
that Trx1 protein expression is induced in hPASMC by exposure to hypoxia and that 
Trx1 protein expression is necessary for hypoxia-induced proliferation in hPASMC.  This 
discovery is important because by regulating the expression of Trx1, we may be able to 
regulate the proliferation of hPASMC in a model of pulmonary hypertension.  
 Following exposure to hypoxia, hPASMC expression of Trx1 protein is increased.  
Normal Trx1 expression is key in maintaining redox balance within these cells.  
Following certain signals, Trx1 is reduced by TrxR and thus can act as an electron donor 
to peroxiredoxin, which acts as a ROS scavenger reducing harmful H2O2 to water within 
the cell.  Because hypoxia is a model for PH, we can conclude that during the course of 
PH, at least initially, Trx1 protein expression is increased and the redox balance of the 
cell is disturbed.  The increase in expression of Trx1 is likely due to the increase of ROS 
within the cell due to hypoxia exposure.  It is the hPASMC’s way of trying to decrease 
the number of ROS, and return to a balanced redox state. 
 Through transfection using an siRNA against the Trx1 protein, we were able to 
successfully knock-down the protein levels of Trx1.  siRNA binds to the site on the cell’s  
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mRNA where Trx1 protein translation occurs, and cuts the mRNA which prevents Trx1 
protein translation.  By doing this, the role of Trx1 protein within the hPASMC’s can be 
studied.  By observing changes in hPASMC behavior in the absence of Trx1, we can 
determine what cellular activities it is an important part of.  That was our reasoning for 
knocking-down its expression in this study, to observe its role in hypoxia-induced 
proliferation of hPASMC. 
 Exposure to hypoxia increased the proliferation of hPASMC.  This is consistent 
with the development of PH in the lung.  This increased proliferation of hPASMC within 
the vessels is what causes the lumen of pulmonary arteries to decrease in size, and 
blood pressure in the lung to increase.  It is important to determine why hypoxia 
exposure leads to the proliferation of hPASMC.   
 The successful knock-down of Trx1 protein prevented hypoxia-induced 
proliferation in hPASMC.  This finding confirms our postulate that Trx1 protein has an 
important role in hPASMC proliferation.  In the hPASMC with no Trx1 protein, the 
proliferation of the hPASMC in hypoxia remained the same as those in normoxia.  
However, in the control group (scramble siRNA), the proliferation of hPASMC in hypoxia 
increased compared to those in normoxia.  We speculate that Trx1 protein may be 
important in regulating the cell cycle, perhaps having a role in controlling checkpoint 
proteins which regulate progression through the cell cycle.  Alternatively, Trx1 protein 
levels may be important in preventing apoptosis, such that in the cells with knock-down 
of Trx1 there is increased apoptosis and therefore decreased viable cell numbers.  
Future studies will examine the mechanism(s) underlying the positive effect of Trx1 on 
hypoxia-induced proliferation of hPASMC.   
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